/

Società

As

Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

89 comunicati stampa

Guarda tutti i comunicati

22/12/2025

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Industria

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Fonte

Emittente

1.00

0

15/12/2025

Industria

Biotecnologia

Salute

Farmaceutica

Oncologia

Scienza

Vetrine/Shopping

Medicina - Varie

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Fonte

Emittente

1.00

0

04/12/2025

Eventi

Biotecnologia

Sanità

Farmaceutica

Salute

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Fonte

Emittente

1.00

0

02/12/2025

Scienza

Cardiologia

Biotecnologia

Farmaceutica

Sanità

Salute

Igiene alimentare

Industria

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Fonte

Emittente

1.00

0

26/11/2025

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Fonte

Emittente

1.00

0

21/11/2025

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Fonte

Emittente

1.00

0

09/11/2025

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Fonte

Emittente

1.00

0

07/11/2025

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Fonte

Emittente

1.00

0

06/11/2025

Biotecnologia

Farmaceutica

Salute

Mercato azionario

AstraZeneca's 9M and Q3 2025 Financial Results

Fonte

Emittente

1.00

0

19/10/2025

Oncologia

Salute

Igiene alimentare

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Eventi

Industria

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0